|
Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Kite, a Gilead company; Novartis |
Research Funding - Novartis |
| |
|
|
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Novartis |
| |
|
Employment - Shoppers Drug Mart (I); Shoppers Drug Mart (I); Shoppers Drug Mart (I); Shoppers Drug Mart (I) |
Travel, Accommodations, Expenses - Novartis; Novartis; Novartis; Novartis |
Other Relationship - Kite/Gilead; Kite/Gilead; Novartis; Novartis |
| |
|
Honoraria - Bellicum Pharmaceuticals; Bluebird Bio; Miltenyi Biotec |
Consulting or Advisory Role - Amgen; Novartis |
| |
|
Honoraria - Amgen; Jazz Pharmaceuticals; Novartis |
Consulting or Advisory Role - Amgen; Jazz Pharmaceuticals; Novartis |
Travel, Accommodations, Expenses - Jazz Pharmaceuticals |
| |
|
Consulting or Advisory Role - Bayer; Lilly; Loxo; Novartis |
Research Funding - Abbvie (Inst); Amgen (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Novella Clinical (Inst); Pfizer (Inst); SERVIER (Inst) |
| |
|
No Relationships to Disclose |
| |
Cristina Diaz de Heredia Rubio |
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Novartis |
Research Funding - Amgen; Gamida Cell; MSD; Novartis; Pharmacyclics |
Travel, Accommodations, Expenses - Jazz Pharmaceuticals; Novartis |
| |
|
Employment - Novartis Pharmaceuticals UK Ltd. |
| |
|
Employment - Novartis Pharmaceuticals UK Ltd. |
Stock and Other Ownership Interests - Novartis |
| |
|
|
| |
Lida Bubuteishvili-Pacaud |
|
| |
|
Consulting or Advisory Role - ADC Therapeutics (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Shire (Inst); SOBI (Inst) |
Travel, Accommodations, Expenses - Neovii |